Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL7120916

N.Nc1ccc(N2CCN(CCCC(=O)O)CC2)cc1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 3/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
RAD52 P43351 1/20 0.51
HTR7 P34969 4/20 0.51
HTR1A P08908 4/20 0.51
CACNA1G O43497 3/20 0.50
CASP6 P55212 1/20 0.49
CYP2D6 P10635 1/20 0.49
KCNH2 Q12809 1/20 0.49
DRD2 P14416 4/20 0.48
HTR2A P28223 3/20 0.48
DRD4 P21917 3/20 0.48
HTR2C P28335 2/20 0.48
DRD3 P35462 2/20 0.48
HRH1 P35367 1/20 0.48
CYP1A2 P05177 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7126140 0.98 GFER (0.53) GFERKDM4EGAAMAPTSMN1; SMN2
SCHEMBL15650606 0.89 GFER (0.56) GFERKDM4EGAAMAPTSMN1; SMN2
SCHEMBL2386501 0.88 GFER (0.54) GFERKDM4EGAAMAPTSMN1; SMN2
SCHEMBL8045431 0.84 KCNH2 (0.69) HTR7HTR1ACACNA1GCYP2D6KCNH2
SCHEMBL9834124 0.84 DRD2 (0.66) GAAHTR7HTR1ACACNA1GDRD2
SCHEMBL19107617 0.84 MAPT (0.58) MAPTHTR7HTR1ACACNA1GKCNH2
SCHEMBL7120917 0.83 GFER (0.49) GFERKDM4EGAAMAPTSMN1; SMN2
SCHEMBL2876290 0.82 GFER (0.51) GFERKDM4EGAAMAPTSMN1; SMN2
SCHEMBL8635007 0.81 DRD4 (0.60) DRD4HRH1ITGB3ITGA2B
SCHEMBL2492875 0.80 DRD2 (0.55) GFERKDM4EDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225078-A1 Derivatives of quinoline as alpha-2 antagonists ORION CORPORATION 2003-12-04 US disclosed
US-6593324-B2 P-aminoanilino- derivatives ORION CORPORATION (FI) 2003-07-15 US disclosed
US-20010046991-A1 Derivatives of quinoline as alpha-2 antagonists OY JUVANTIA PHARMA LTD. (FI) 2001-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225078-A1 Derivatives of quinoline as alpha-2 antagonists ADRB2, ADRA2A, ADRB1 GFER 4190/4885KDM4E 3467/4885GAA 1580/4885
US-20010046991-A1 Derivatives of quinoline as alpha-2 antagonists ADRB2, ADRA2A, ADRB1 GFER 4190/4885KDM4E 3467/4885GAA 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.